Cleerly

We envision a future where heart disease diagnosis and prevention are transformed through precise, AI-driven insights, enabling tailored care that saves lives and improves patient outcomes globally.

At Cleerly, we harness advanced machine learning and medical imaging technology to reveal the unseen complexities of coronary artery disease, empowering clinicians with actionable, personalized data that goes beyond traditional methods.

Our mission is to establish a new standard of cardiac care by delivering earlier, more accurate detection and prediction tools, shaping a future where cardiovascular health is proactively managed with clarity and confidence.

We've been tracking Cleerly for a while now, and frankly, we're impressed by what they've built. This isn't another flashy health tech startup promising the moon — it's a company that's actually cracked one of medicine's toughest nuts: making sense of heart imaging data at scale.

Their AI platform analyzes those complex coronary CT scans (CCTA images, if you want to get technical) and spots plaque buildup that human eyes might miss. More importantly, it predicts which patients are actually at risk of having a heart attack. That's the kind of practical AI application that gets us excited.

The Tech That Actually Works

Here's what caught our attention: Cleerly didn't just train their algorithms on a handful of images and call it a day. They've validated their machine learning models using over 10 million images and 40,000 patient studies spanning 15 years. That's serious data science.

The platform creates detailed 3D models of coronary arteries, identifying different types of plaque and measuring how much blood flow is restricted. It's like having a super-powered radiologist that never gets tired or misses subtle details.

Insurance Companies Are Paying Attention

What really tells us Cleerly is onto something? Major insurers like UnitedHealthcare and Cigna started covering their Advanced Plaque Analysis service. When insurance companies open their wallets for new technology, you know it's delivering real clinical value.

This coverage expansion means millions of Americans can now access Cleerly's AI analysis without breaking the bank. That's a game-changer for adoption.

Who Benefits Most

Cleerly isn't trying to be everything to everyone — and we respect that focus. Their sweet spot is cardiologists and healthcare systems dealing with patients who come in with chest pain. These are the cases where getting the diagnosis right the first time really matters.

The platform integrates smoothly with existing clinical workflows, which means doctors don't have to completely overhaul how they work. Smart move. We've seen too many promising health tech tools fail because they made life harder for busy physicians.

With $106 million in funding and FDA clearance in their back pocket, Cleerly has the resources and regulatory approval to scale meaningfully. Their ongoing TRANSFORM trial comparing AI-guided care with standard treatment should provide even more validation. We're definitely keeping an eye on this one.